Change in Hemoglobin A1c and C-Reactive Protein Levels in Patients With Diabetes Mellitus
Sameed Ahmed M. Khatana BS
From the Target Research Enhancement Program at the Providence Veterans Affairs Medical Center, Providence, RI;
Search for more papers by this authorTracey H. Taveira PharmD
From the Target Research Enhancement Program at the Providence Veterans Affairs Medical Center, Providence, RI;
University of Rhode Island College of Pharmacy, Kingston, RI;
Search for more papers by this authorGaurav Choudhary MD
From the Target Research Enhancement Program at the Providence Veterans Affairs Medical Center, Providence, RI;
Departments of Medicine at the Providence Veterans Affairs Medical Center;
Search for more papers by this authorCharles B. Eaton MD
Family Medicine at Memorial Hospital of Rhode Island;, Warren Alpert Medical School of Brown University, Providence, RI
Search for more papers by this authorWen-Chih Wu MD
From the Target Research Enhancement Program at the Providence Veterans Affairs Medical Center, Providence, RI;
Departments of Medicine at the Providence Veterans Affairs Medical Center;
Search for more papers by this authorSameed Ahmed M. Khatana BS
From the Target Research Enhancement Program at the Providence Veterans Affairs Medical Center, Providence, RI;
Search for more papers by this authorTracey H. Taveira PharmD
From the Target Research Enhancement Program at the Providence Veterans Affairs Medical Center, Providence, RI;
University of Rhode Island College of Pharmacy, Kingston, RI;
Search for more papers by this authorGaurav Choudhary MD
From the Target Research Enhancement Program at the Providence Veterans Affairs Medical Center, Providence, RI;
Departments of Medicine at the Providence Veterans Affairs Medical Center;
Search for more papers by this authorCharles B. Eaton MD
Family Medicine at Memorial Hospital of Rhode Island;, Warren Alpert Medical School of Brown University, Providence, RI
Search for more papers by this authorWen-Chih Wu MD
From the Target Research Enhancement Program at the Providence Veterans Affairs Medical Center, Providence, RI;
Departments of Medicine at the Providence Veterans Affairs Medical Center;
Search for more papers by this authorAbstract
The authors studied the effects on C-reactive protein (CRP) levels of an intensive intervention to reduce hemoglobin A1c (HbA1c) among 58 veterans with type 2 diabetes. Weekly group sessions of behavioral and pharmacologic intervention were conducted for 4 weeks at Providence Veterans Affairs Medical Center. Change in cardiovascular risk factors and CRP levels were compared at baseline and 3 months postintervention. There was a significant decrease in HbA1c (−0.7%±1.9%, P<.01), total cholesterol (−20.3±41.1 mg/dL, P=.01), low-density lipoprotein cholesterol (−11.7±31.4 mg/dL, P=.05), systolic blood pressure (−6.9±21.2 mm Hg, P=.03), and diastolic blood pressure (−6.0±10.6 mm Hg, P<.01) over 4 months. There was no significant change in CRP levels (1.1±6.6 mg/L, P=.2). These results suggest that CRP effects may not be adequate to predict changes in cardiovascular risk among diabetic patients and should not be a surrogate for achieving evidence-based goals in traditional cardiovascular risk factors.
References
- 1 Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004; 141: 421–431.
- 2 Nathan DM, Cleary PA, Backlund JY, et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353: 2643–2653.
- 3 Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and Cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003; 348: 383–393.
- 4 The United Kingdom Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998; 352: 854–865.
- 5 Kuller LH, Tracy RP, Shaten J, et al. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Am J Epidemiol. 1996; 144: 537–547.
- 6 Ridker PM, Buring JE, Shih J, et al. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation. 1998; 98: 731–733.
- 7 Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347: 1557–1565.
- 8 Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350: 1387–1397.
- 9 Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001; 286: 327–334.
- 10 Dandona P, Aljada A, Bandyopadhyay A. Inflammation: the link between insulin resistance, obesity and diabetes. Trends Immunol. 2004; 25: 4–7.
- 11 The United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UDPDS 33). Lancet. 1998; 352: 837–853.
- 12 Akbar DH. Effect of metformin and sulfonylurea on C-reactive protein level in well-controlled type 2 diabetics with metabolic syndrome. Endocrinology. 2003; 20: 215–218.
- 13 Nakamura H, Ito H, Egami Y, et al. Waist circumference is the main determinant of elevated C-reactive protein in metabolic syndrome. Nutrition. 2008; 24: 401–406.
- 14 Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006; 355: 2631–2639.
- 15 Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med. 2005; 352: 20–28.
- 16 Takase H, Nakazawa A, Yamashita S, et al. Pioglitazone produces rapid and persistent reduction of vascular inflammation in patients with hypertension and type 2 diabetes mellitus who are receiving angiotensin II receptor blockers. Metabolism. 2007; 56: 559–564.
- 17 Wolever TM, Gibbs AL, Mehling C, et al. The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. Am J Clin Nutr. 2008; 87: 114–125.
- 18 Ridker PM, Buring JE, Cook NR, et al. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events an 8-year follow-up of 14 719 initially healthy American women. Circulation. 2003; 107: 391–397.
- 19 Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006; 48: 73–79.
- 20 Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286: 64–70.
- 21 Tan KCB, Chow WS, Tam SCF, et al. Atorvastatin lowers C-reactive protein and improves endothelium-dependent vasodilation in type 2 diabetes mellitus. J Clin Endocrinol Metab. 2002; 87: 563–568.
- 22 Voleti B, Agrawal A. Statins and nitric oxide reduce C-reactive protein production while inflammatory conditions persist. Mol Immunol. 2006; 43: 891–896.
- 23 Okita K, Nishijima H, Murakami T, et al. Can exercise training with weight loss lower serum C-reactive protein levels? Arterioscler Thromb Vasc Biol.. 2004; 24: 1868–1873.
- 24 Dekker MJ, Lee S, Hudson R, et al. An exercise intervention without weight loss decreases circulating interleukin-6 in lean and obese men with and without type 2 diabetes mellitus. Metabolism. 2007; 56: 332–338.
- 25 Griffith JA, Ma Y, Chasan-Taber L, et al. Association between dietary glycemic index, glycemic load, and high-sensitivity C-reactive protein. Nutrition. 2008; 24: 401–406.
- 26 Plenge JK, Hernandez TL, Weil KM, et al. Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation. 2002; 106: 1447–1452.
- 27 Ridker PM, Fonseca FA, Genest J, et al. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Am J Cardiol. 2007; 100: 1659–1664.
